1-5 of 5
Authors: Howard Burris
Journal Article
ACTR-31. PHASE 1 STUDY OF AG-881, AN INHIBITOR OF MUTANT IDH1 AND IDH2: RESULTS FROM THE RECURRENT/PROGRESSIVE GLIOMA POPULATION Free
Neuro-Oncology, Volume 20, Issue suppl_6, November 2018, Page vi18, https://doi.org/10.1093/neuonc/noy148.064
Published: 05 November 2018
Journal Article
ACTR-46. AG-120, A FIRST-IN-class MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: UPDATED RESULTS FROM THE PHASE 1 NON-ENHANCING GLIOMA POPULATION Free
Neuro-Oncology, Volume 19, Issue suppl_6, November 2017, Pages vi10–vi11, https://doi.org/10.1093/neuonc/nox168.037
Published: 06 November 2017
Journal Article
ACTR-45. A PHASE IB STUDY EVALUATING THE C-MET INHIBITOR INC280 IN COMBINATION WITH BEVACIZUMAB IN GLIOBLASTOMA MULTIFORME (GBM) PATIENTS Free
Neuro-Oncology, Volume 18, Issue suppl_6, November 2016, Pages vi11–vi12, https://doi.org/10.1093/neuonc/now212.043
Published: 07 November 2016
Journal Article
ACTR-46. AG120, A FIRST-IN-CLASS MUTANT IDH1 INHIBITOR IN PATIENTS WITH RECURRENT OR PROGRESSIVE IDH1 MUTANT GLIOMA: RESULTS FROM THE PHASE 1 GLIOMA EXPANSION COHORTS Free
Neuro-Oncology, Volume 18, Issue suppl_6, November 2016, Page vi12, https://doi.org/10.1093/neuonc/now212.044
Published: 07 November 2016
Journal Article
ATNT-26PHASE I/II STUDY OF DIANHYDROGALACTITOL IN PATIENTS WITH RECURRENT MALIGNANT GLIOMA Free
Neuro-Oncology, Volume 17, Issue suppl_5, November 2015, Page v16, https://doi.org/10.1093/neuonc/nov205.26
Published: 09 November 2015
